- Home
- CCIF vs BMEA Comparison
CCIF vs BMEA Comparison
Compare CCIF & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- BMEA
- Stock Information
- Founded
- CCIF 2011
- BMEA 2017
- Country
- CCIF United States
- BMEA United States
- Employees
- CCIF N/A
- BMEA N/A
- Industry
- CCIF Finance/Investors Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- BMEA Health Care
- Exchange
- CCIF Nasdaq
- BMEA Nasdaq
- Market Cap
- CCIF 111.5M
- BMEA 125.0M
- IPO Year
- CCIF N/A
- BMEA 2021
- Fundamental
- Price
- CCIF $5.28
- BMEA $1.35
- Analyst Decision
- CCIF
- BMEA Strong Buy
- Analyst Count
- CCIF 0
- BMEA 8
- Target Price
- CCIF N/A
- BMEA $10.63
- AVG Volume (30 Days)
- CCIF 76.9K
- BMEA 3.9M
- Earning Date
- CCIF 01-01-0001
- BMEA 10-29-2025
- Dividend Yield
- CCIF 25.90%
- BMEA N/A
- EPS Growth
- CCIF N/A
- BMEA N/A
- EPS
- CCIF N/A
- BMEA N/A
- Revenue
- CCIF N/A
- BMEA N/A
- Revenue This Year
- CCIF N/A
- BMEA N/A
- Revenue Next Year
- CCIF N/A
- BMEA N/A
- P/E Ratio
- CCIF N/A
- BMEA N/A
- Revenue Growth
- CCIF N/A
- BMEA N/A
- 52 Week Low
- CCIF $7.43
- BMEA $1.29
- 52 Week High
- CCIF $10.16
- BMEA $12.18
- Technical
- Relative Strength Index (RSI)
- CCIF 40.39
- BMEA 34.98
- Support Level
- CCIF $5.17
- BMEA $1.34
- Resistance Level
- CCIF $5.29
- BMEA $1.50
- Average True Range (ATR)
- CCIF 0.13
- BMEA 0.10
- MACD
- CCIF 0.00
- BMEA -0.02
- Stochastic Oscillator
- CCIF 31.22
- BMEA 1.10
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.